Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells

International Journal of Cancer

Volumn 68, Issue 5, 1996, Pages 644-649

  Batra, Satish ^a,b   Karlsson, Richard ^a   Witt, Lisbeth ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTRAMUSTINE; GLYCOPROTEIN P; TAMOXIFEN; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG SYNERGISM; ESTRAMUSTINE; HUMANS; MALE; PROSTATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0029828880     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19961127)68:5<644::AID-IJC15>3.0.CO;2-1     Document Type: Article

References (14)

1. BATRA, S. and LARSSON, I., Binding of vinblastine and estramustine to isolated plasma membrane fractions from human prostate and prostatic tumors. Cancer Lett. 106, 217-220 (1996).
2. DAHLLöF, B., BILLSTRöM, A., CABRAL, F. and HARTLEY-ASP, B., Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res., 53, 4573-4581 (1993).
3. HUDES, G.R., GREENBERG, R., KRIGEL, R.L., Fox, S., SCHER, R., LiTWiN, S., WATTS, P., SPEICHER, L., TEW, K. and COMIS, R., Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. din. Oncol, 10, 1754-1761 (1992).
4. LAEMMLI, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Land.), 227, 680-685 (1970).
5. NELSON, R.L., The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med.pediatr. Oncol., 10, 115-127(1982).
6. SEIDMAN, A.D., SCHER, H.I., PETRYLAK, D., DERSHAW, D.D. and CURLEY, T., Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.J. Urol., 147, 931-934(1992).
7. SIEGSMUND, M.J., CARDARELLI, C, AKSENTIJEVICH, I., SUGIMOTO, Y., PASTAN, I. and GOTTESMAN, M.M., Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells.J. Urol., 151, 485-491 (1994).
8. SIEGSMUND, M.J., KREUKLER, C, STEIDLER, A., KöHRMANN, K.U. and ALKEN, P., P-glycoprotein mediated multidrug resistance in androgen independent prostate carcinoma cells. Urol. Res., 23, 38A (1995).
9. SMITH, P.K., KROHN, R.I., HERMANSON, G.T., MALLIA, A.K., GARTNER, F.H., PROVENZANO, M.D., FUJIMOTO, E.K., GOEKE, N.M., OLSON, B.J. and KLENK, D.C., Measurement of protein using bicinchoninic acid [erratum appears in Anal. Biochem., 163, 279 (1987)].
10. Anal Biochem., 150, 76-85 (1985).
11. SPEICHER, L.A., BARONE, L.R., CHAPMAN, A.E., HUDES, G.R., LAING, N., SMITH, C.D. and TEW, K.D., P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine. J. not. Cancer Inst., 86, 688-694 (1994).
12. STEARNS, M.E. and TEW, K.D., Estramustine binds MAP-2 to inhibit microtubule assembly m vitro. J. Cell Sei., 89, 331-342 (1988).
13. STEARNS, M.E., WANG, M., TEW, K.D. and BINDER, L.I., Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.J. CellBiol, 107, 2647-2656 (1988).
14. YANG, C.P., SHEN, H.J. and HORWITZ, S.B., Modulation of the function of P-glycoprotein by estramustine. J. nat. Cancer Inst., 86, 723-725 (1994).